WCMNY
BPMC

Westchester Capital Management (New York)’s Blueprint Medicines BPMC Stock Holding History

Westchester Capital Management (New York)’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-64,928
Closed -$8.32M – 261
2025
Q2 		$8.32M Buy
+64,928
New +$6.74M 0.44% 48

Other funds holding BPMC

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Westchester Capital Management (New York)'s BPMC Position: Q3 2025 in Review

Westchester Capital Management (New York) sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 64,928 shares — an estimated $8.32M sold.

Westchester Capital Management (New York) first reported a position in BPMC in Q2 2025 and held it in 1 quarter. The position peaked at $8.32M in Q2 2025. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

  • Westchester Capital Management (New York) reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
  • Westchester Capital Management (New York) sold 64,928 Blueprint Medicines shares in Q3 2025, an estimated $8.32M.
  • Westchester Capital Management (New York) first reported a position in Blueprint Medicines in Q2 2025 and held it in 1 quarter.
  • Westchester Capital Management (New York)'s Blueprint Medicines position peaked at $8.32M in Q2 2025.
  • 5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on Westchester Capital Management (New York)'s 13F filing for Q3 2025, filed 14 Nov 2025.